Uzbekistan

Uzbekistan is rapidly emerging as a central hub for the Central Asian life sciences ecosystem, driven by aggressive government reforms and the landmark Tashkent Pharma Park innovative cluster.

The nation is best known for its robust pharmaceutical manufacturing sector, with the government targeting a production value of $697 million by late 2026 through significant foreign direct investment (FDI) and technology transfer incentives.

Strategic partnerships with South Korea and EU-based firms are accelerating the local production of biotechnology medicines and high-demand generics, supported by new simplified state registration regulations for medicinal products and medical devices.

In the healthcare innovation space, Uzbekistan is integrating artificial intelligence (AI) into health financing and clinical diagnostics to achieve universal health coverage and improve patient outcomes.

The country’s biotechnology sector is bolstered by the newly established National Research Institute of Biopharmaceuticals, which focuses on vaccine development and cell-based therapies.

Global life sciences stakeholders are increasingly drawn to the region's medical device industry, which now utilizes a risk-based classification system aligned with international standards to streamline market entry.

Furthermore, academic research in Uzbekistan is anchored by the Academy of Sciences and specialized medical universities that facilitate clinical trials and basic research in oncology and cardiovascular health.

With mandatory Good Manufacturing Practice (GMP) compliance and the introduction of bioequivalence study requirements, Uzbekistan is elevating its regulatory framework to meet global quality benchmarks.

This transformation positions the country as a strategic gateway for companies seeking to scale life sciences solutions across the CIS region and beyond.